Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo).

Date publication

janvier 2019

Journal

Lung cancer (Amsterdam, Netherlands)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr FOUCHER Pascal

Tous les auteurs :
Halmos B, Tan EH, Soo RA, Cadranel J, Lee MK, Foucher P, Hsia TC, Hochmair M, Griesinger F, Hida T, Kim E, Melosky B, Märten A, Carcereny E

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/30642537

Résumé

In the LUX-Lung clinical trials of afatinib in EGFR mutation-positive NSCLC, tolerability-guided dose adjustment reduced the incidence and severity of adverse events while maintaining efficacy. The RealGiDo study evaluated the impact of afatinib dose adjustment in a real-world setting.

Mots clés

Afatinib, EGFR mutation-positive, Non-small-cell lung cancer, Real-world study

Référence

Lung Cancer. 2019 Jan;127:103-111